Join Us to Learn About XPOVIO Neoadjuvant HER2+Colorectal Cancer Interactive Tools New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer Recent Advances in Small-Cell Lung Cancer

Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma

Insights Medical World News News Network OncLive TV Peer Exchange Podcasts Rapid Readouts The Talk

Giants of Cancer Care OncLive Events Scientific Interchange Workshop Series PER Events State of the Science Summit / IPC Webinars

CME Community Interactive Tools Partners Pipeline Report Sponsored

Advertise
News
About OncLive
Editorial Board
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2020 MJH Life Sciences and OncLive. All rights reserved.

Spotlight

Join Us to Learn About XPOVIO
Neoadjuvant HER2+
Colorectal Cancer
Interactive Tools
New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer
Recent Advances in Small-Cell Lung Cancer

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

OncLive SOSS

Advertise
News
About OncLive
Editorial Board
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2020 MJH Life Sciences^™ and OncLive. All rights reserved.

Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis

June 16, 2020

Petros Grivas MD, PhD, Seattle Cancer Care Alliance

x